Drugs for Common Variable Immunodeficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 95)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Rifaximin |
Approved, Investigational |
Phase 4 |
|
80621-81-4 |
6436173 46783403 |
Synonyms:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV
80621-81-4
88747-56-2
AC-19112
alpha-0817185
Bio-0556
BRN 3584528
C43H51N3O11
CHEMBL1617
D02554
DB01220
Fatroximin
Flonorm
L 105
L 105 (Ansamacrolide antibiotic)
L 105SV
Lormyx
LS-178059
LS-64147
Lumenax
MLS000759430
Normix
Redactiv
|
RedActiv
Rifacol
Rifamixin
Rifamycin L 105
Rifamycin L 105SV
Rifaxidin
Rifaximin
Rifaximin (USAN/INN)
Rifaximin [USAN:INN]
Rifaximina
Rifaximina [Spanish]
Rifaximine
Rifaximine [French]
Rifaximinum
Rifaximinum [Latin]
Rifaximinun
Rifaxin
Ritacol
S1790_Selleck
SMR000466324
Spiraxin
UNII-L36O5T016N
Xifaxan
Xifaxan, Rifacol, Fatroximin, Rifaximin
Xifaxsan
Xifaxsan (TN)
|
|
2 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
63006 5281004 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
Budesónida
budesonide
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
|
HMS1921I22
HMS2094I13
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
3 |
|
Rho(D) Immune Globulin |
|
Phase 4 |
|
|
|
4 |
|
gamma-Globulins |
|
Phase 4 |
|
|
|
5 |
|
Complement C1 Inactivator Proteins |
|
Phase 4 |
|
|
|
6 |
|
Complement C1 Inhibitor Protein |
|
Phase 4 |
|
|
|
7 |
|
Complement C1s |
|
Phase 4 |
|
|
|
8 |
|
Hormones |
|
Phase 4 |
|
|
|
9 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
10 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
11 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
12 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
13 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
14 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
15 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
16 |
|
Antibodies |
|
Phase 4 |
|
|
|
17 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
18 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
19 |
|
Immunoglobulin G |
|
Phase 4 |
|
|
|
20 |
|
Proline |
Nutraceutical |
Phase 3 |
|
147-85-3 |
145742 |
Synonyms:
(−)-(S)-proline
(-)-(S)-Proline
(-)-2-Pyrrolidinecarboxylate
(−)-2-pyrrolidinecarboxylic acid
(-)-2-Pyrrolidinecarboxylic acid
(−)-proline
(-)-Proline
(-)-Proline (S)-2-Carboxypyrrolidine
(2S)-Pyrrolidine-2-carboxylate
(2S)-pyrrolidine-2-carboxylic acid
(2S)-Pyrrolidine-2-carboxylic acid
(L)-PROLINE
(S)-(-)-Proline
(S)-(-)-Pyrrolidine-2-carboxylate
(S)-(-)-Pyrrolidine-2-carboxylic acid
(S)-2-Carboxypyrrolidine
(S)-2-Pyrralidinecarboxylate
(S)-2-Pyrralidinecarboxylic acid
(S)-2-Pyrrolidinecarboxylate
(S)-2-Pyrrolidinecarboxylic acid
(S)-Proline
(S)-Pyrrolidine-2-carboxylate
(S)-pyrrolidine-2-carboxylic acid
(S)-Pyrrolidine-2-carboxylic acid
147-85-3
18875-45-1
2-Pyrrolidinecarboxylate
2-pyrrolidinecarboxylic acid
2-Pyrrolidinecarboxylic acid
37159-97-0
4305-67-3
4607-28-7
608998_ALDRICH
81709_FLUKA
81709_SIGMA
81710_FLUKA
81710_SIGMA
A01B5B63-CC3D-4796-A7B4-C2DE26A6FA93
AB1002323
AC-11190
AC1L3RTC
AC1Q71B7
AI3-26710
AmbotzHAA1126
bmse000047
C00148
Carboxypyrrolidine
CB 1707
CHEBI:17203
CHEMBL54922
CID145742
D00035
DB00172
DB02853
EINECS 205-702-2
|
FEMA No. 3319
FEMA Number 3319
H-Pro-OH
HSDB 1210
L Proline
L-(−)-proline
L-(-)-Proline
L-(2,3-3H)Proline
L-alpha-Pyrrolidinecarboxylate
L-alpha-pyrrolidinecarboxylic acid
L-alpha-Pyrrolidinecarboxylic acid
L-a-Pyrrolidinecarboxylate
L-a-Pyrrolidinecarboxylic acid
L-Prolin
L-proline
L-Proline
L-Proline (JAN)
L-Proline, labeled with carbon-14
L-Proline-15N
L-Pyrrolidine-2-carboxylate
L-pyrrolidine-2-carboxylic acid
L-Pyrrolidine-2-carboxylic acid
LS-2381
L-α-pyrrolidinecarboxylate
L-α-pyrrolidinecarboxylic acid
MolPort-001-757-108
NCGC00014017
NCGC00097126-01
nchembio.186-comp54
nchembio816-comp9
NSC 46703
NSC-97923
P
P0380_SIAL
P0481
P5607_SIGMA
P8865_SIAL
P8865_SIGMA
pro
PRO (IUPAC abbreviation)
prolina
Prolina
Prolina [Spanish]
proline
Proline
PROLINE
Proline (USP)
Proline (VAN)
Proline [USAN:INN]
Prolinum
Prolinum [Latin]
TL80073505
UNII-9DLQ4CIU6V
W331902_ALDRICH
|
|
21 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 2 |
|
198153-51-4 |
5360545 |
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
PEG-IFN alfa-2A
Peginterferon alfa-2a
PEG-Interferon alfa-2A
|
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Peginterferon alfa-2a (USAN/INN)
Pegylated Interfeaon alfa-2A
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
|
|
22 |
|
Thiotepa |
Approved, Investigational |
Phase 2 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
Tepadina
Tespa
Tespamin
thio Tepa
Thiophosphamide
|
Thioplex
thio-Tepa
Thiotepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
23 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
460612 4053 |
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
Medphalan
|
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
P-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
P-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
24 |
|
Mesna |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-mercaptoethanesulfonic acid
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-mercaptoethanesulphonic acid
2-Mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-sulfanylethylsulfonate
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
|
Bristol myers squibb brand OF mesna
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzima M
Coenzym m
Coenzym M
Coenzyme m
CoM
HS-CoM
Kendrick brand OF mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
reduced coenzyme M
Reduced coenzyme m
reduced CoM
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
β-mercaptoethanesulfonate
β-mercaptoethanesulfonic acid
β-mercaptoethanesulphonate
β-mercaptoethanesulphonic acid
|
|
25 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865 |
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
26 |
|
Dipyridamole |
Approved |
Phase 2 |
|
58-32-2 |
3108 |
Synonyms:
2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine
2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
4-26-00-03840 (Beilstein Handbook Reference)
58-32-2
AB00051974
AC-18100
AC1L1F6T
AC1Q7CXU
AC1Q7CXW
AC1Q7CXX
Agilease
AKOS000509426
Anginal
Antistenocardin
apo-Dipyridamole
Apo-Dipyridamole
Apo-Dipyridamole Fc
Apo-Dipyridamole Sc
Apotex brand OF dipyridamole
Apotex Brand of Dipyridamole
Apricor
Ashbourne brand OF dipyridamole
Ashbourne Brand of Dipyridamole
BAS 00818792
Belmac brand OF dipyridamole
Belmac Brand of Dipyridamole
Berlin chemie brand OF dipyridamole
Berlin Chemie Brand of Dipyridamole
Berlin-chemie brand OF dipyridamole
Berlin-Chemie Brand of Dipyridamole
BIM-0050449.0001
Bio-0173
Boehringer ingelheim brand OF dipyridamole
Boehringer Ingelheim Brand of Dipyridamole
BPBio1_000270
BRD-K86301799-001-04-1
BRN 0068373
BSPBio_000244
BSPBio_001554
BSPBio_001924
C24H40N8O4
Cardioflux
Cardoxil
Cardoxin
CAS-58-32-2
Cerebrovase
CHEBI:4653
CHEMBL932
Chilcolan
CID3108
Cleridium
Cléridium
Cleridium 150
Coribon
Coridil
Coronarine
Corosan
Coroxin
CPD000058382
Curantil
Curantyl
D 9766
D00302
D004176
D2274
D9766_SIGMA
DB00975
Dipiridamol
Dipiridamol [INN-Spanish]
Dipyramidole
Dipyridamine
Dipyridamol
dipyridamole
Dipyridamole
Dipyridamole (JP15/USP/INN)
Dipyridamole [USAN:INN:BAN:JAN]
Dipyridamolum
Dipyridamolum [INN-Latin]
Dipyridan
Dipyudamine
DivK1c_000696
Dypyridamol
EINECS 200-374-7
EU-0100464
Gulliostin
HMS1568M06
HMS1791N16
HMS1920I10
HMS1989N16
|
HMS2089N15
HMS2091O18
HMS502C18
IDI1_000696
IPRAD brand OF dipyridamole
IPRAD Brand of Dipyridamole
Iv Persantine
Justpertin
KBio1_000696
KBio2_001484
KBio2_004052
KBio2_006620
KBio3_001144
KBioGR_001123
KBioSS_001484
Kurantil
Lopac0_000464
Lopac-D-9766
LS-66732
Miosen
MLS000028420
MLS001076306
MLS001333724
MolPort-001-792-504
Natyl
NCGC00015385-01
NCGC00015385-02
NCGC00015385-03
NCGC00015385-07
NCGC00015385-15
NCGC00023914-02
NCGC00023914-04
NCGC00023914-05
NCGC00023914-06
NCGC00023914-07
NCGC00023914-08
NCGC00023914-09
NCGC00023914-10
NCGC00023914-11
NCI60_005689
NINDS_000696
novo-Dipiradol
Novo-Dipiradol
Novopharm brand OF dipyridamole
Novopharm Brand of Dipyridamole
NSC 515776
NSC515776
NSC-515776
Peridamol
Permiltin
Permole, Persantine, Dipyridan, Dipyridamole
Persantin
Persantine
Persantine (TN)
Piroan
Prandiol
Prandiol 75
Prestwick_145
Prestwick0_000142
Prestwick1_000142
Prestwick2_000142
Prestwick3_000142
Protangix
RA 8
RA-8
S1867_Selleck
S1895_Selleck
SAM002264609
SMP2_000208
SMR000058382
SPBio_001003
SPBio_002183
Spectrum_001004
SPECTRUM1500259
Spectrum2_000972
Spectrum3_000402
Spectrum4_000522
Spectrum5_000839
Stenocardil
Stenocardiol
Stimolcardio
Tocris-0691
UNII-64ALC7F90C
UPCMLD-DP072
UPCMLD-DP072:001
Usaf ge-12
Usaf Ge-12
WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q
ZINC00643046
|
|
27 |
|
Pentostatin |
Approved, Investigational |
Phase 2 |
|
53910-25-1 |
439693 40926 |
Synonyms:
(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
2' Deoxycoformycin
2'-DCF
2'-Deoxycoformycin
2'-Dexoycoformycin
53910-25-1
59979-24-7
AC1L97UQ
BIDD:GT0136
C02267
CHEBI:41829
CHEMBL1580
CI-825
CID439693
CL-67310465
co Vidarabine
Coforin
Co-V
Covidarabine
Co-vidarabine
CO-Vidarabine
|
D00155
DB00552
dCF
Deoxycoformycin
Lederle brand OF pentostatin
Nipent
Nipent (TN)
Oncopent
PD-81565
PD-ADI
pentostatin
Pentostatin
Pentostatin (JAN/USAN/INN)
Pentostatina
Pentostatine
Pentostatinum
Prasfarma brand OF pentostatin
Supergen brand OF pentostatin
Vidarbine
Vira A deaminase inhibitor
Warner-lambert brand OF pentostatin
Wyeth brand OF pentostatin
|
|
28 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 46835353 |
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
Sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
Sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
29 |
|
Hydroxyurea |
Approved |
Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
30 |
|
Ustekinumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
815610-63-0 |
|
Synonyms:
|
31 |
|
Fludarabine |
Approved |
Phase 2 |
|
21679-14-1, 75607-67-9 |
30751 |
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-fluoro-ARA AMP
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
AC1LCW8I
AC1Q51CF
Beneflur
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
|
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
FaraAMP
F-Ara-AMP
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
fluoro-Ara-AMP
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
32 |
|
alemtuzumab |
Approved, Investigational |
Phase 2 |
|
216503-57-0 |
|
Synonyms:
|
33 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
glaxo Wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
34 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
35 |
|
Mycophenolic acid |
Approved |
Phase 2 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acid, mycophenolic
Acide mycophenolique
acido Micofenolico
Acido micofenolico
Acidum mycophenolicum
Melbex
|
micofenolico acido
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic acid
Mycophenolsaeure
Mycophenolsäure
Myfortic
|
|
36 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
37 |
|
Interferon alpha-2 |
|
Phase 2 |
|
|
|
38 |
|
interferons |
|
Phase 2 |
|
|
|
39 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
40 |
|
Thymoglobulin |
|
Phase 1, Phase 2 |
|
|
|
41 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
42 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
43 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
44 |
|
Interleukin-12 |
|
Phase 1, Phase 2 |
|
|
|
45 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
46 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
47 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
48 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
49 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
50 |
|
Calcineurin Inhibitors |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 63)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial |
Completed |
NCT01946906 |
Phase 4 |
Rifaximin |
2 |
A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID) |
Completed |
NCT00520494 |
Phase 4 |
Vivaglobin |
3 |
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents |
Completed |
NCT01289847 |
Phase 4 |
|
4 |
Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases. |
Completed |
NCT00634569 |
Phase 4 |
|
5 |
A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions |
Recruiting |
NCT03576469 |
Phase 4 |
|
6 |
Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies |
Recruiting |
NCT03866538 |
Phase 4 |
Withdrawal of Oral Budesonide |
7 |
Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study |
Suspended |
NCT03737617 |
Phase 4 |
Cuvitru 20 % Injectable Solution |
8 |
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients. |
Completed |
NCT02247141 |
Phase 3 |
|
9 |
A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of Gammaplex® in Primary Immunodeficiency Diseases |
Completed |
NCT00278954 |
Phase 3 |
|
10 |
A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID) |
Completed |
NCT00168025 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
11 |
An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID) |
Completed |
NCT00168012 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
12 |
A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID) |
Completed |
NCT00322556 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
13 |
A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency |
Completed |
NCT00542997 |
Phase 3 |
|
14 |
A Clinical Study of Immune Globulin Intravenous (Human) Omr-IgG-am IGIV in Subjects With Primary Immune Deficiency Diseases |
Completed |
NCT00468273 |
Phase 3 |
Immune Globulin Intravenous (Human) Omr-IgG-am IGIV |
15 |
A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases |
Completed |
NCT01884311 |
Phase 3 |
|
16 |
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases |
Completed |
NCT01963143 |
Phase 3 |
|
17 |
A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID) |
Completed |
NCT00719680 |
Phase 3 |
|
18 |
IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients |
Completed |
NCT00220766 |
Phase 3 |
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water |
19 |
An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor-blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 in Patients With APDS/PASLI |
Recruiting |
NCT02435173 |
Phase 2, Phase 3 |
CDZ173 |
20 |
Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial |
Unknown status |
NCT02661477 |
Phase 2 |
pegylated interferon alfa 2 |
21 |
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime |
Recruiting |
NCT01821781 |
Phase 2 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
22 |
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders |
Recruiting |
NCT03513328 |
Phase 1, Phase 2 |
Thiotepa--single daily dose;Thiotepa--escalated dose |
23 |
A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients |
Recruiting |
NCT04424901 |
Phase 2 |
Dipyridamole |
24 |
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies |
Recruiting |
NCT02579967 |
Phase 2 |
Immunosuppression Only Conditioning - Closed with amendment L;Reduced Intensity Conditioning;Myeloablative Conditioning-Closed with amendment L;GVHD Prophylaxis |
25 |
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation |
Recruiting |
NCT03663933 |
Phase 2 |
Immunosuppression Only Conditioning (IOC);Reduced Intensity Conditioning (RIC);GVHD Prophylaxis |
26 |
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation |
Recruiting |
NCT01962415 |
Phase 2 |
Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa |
27 |
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
Active, not recruiting |
NCT02199496 |
Phase 1, Phase 2 |
|
28 |
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors |
Enrolling by invitation |
NCT01852370 |
Phase 1, Phase 2 |
|
29 |
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immunodeficiency Diseases |
Not yet recruiting |
NCT04339777 |
Phase 2 |
Busulfan test dose;Fludarabine;Busulfan;Alemtuzumab;Tacrolimus (Tacro);Mycophenolate mofetil (MMF);Cyclophosphamide (Cytoxan) |
30 |
Randomised, Multicentric, Phase ii Study of the Immunogenicity of a "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency |
Terminated |
NCT01489618 |
Phase 2 |
|
31 |
Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) |
Withdrawn |
NCT02789397 |
Phase 2 |
Rituximab (RTX) and Azathioprine (AZA);Placebos |
32 |
A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
Completed |
NCT00263237 |
Phase 1 |
STA-5326 |
33 |
A Phase I Dose Escalation Study of B-Lymphocyte Stimulator (BLyS) Administered Subcutaneously in Patients With Selective IgA Deficiency |
Completed |
NCT00024934 |
Phase 1 |
B-Lymphocyte Stimulator (BLyS) |
34 |
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency |
Recruiting |
NCT03968211 |
Phase 1 |
|
35 |
Investigation of the Lymphocyte Surface Expression of Patients With Primary Immunodeficiency (Common Variable Immunodeficiency (CVID)), Compared to Controls |
Unknown status |
NCT01196702 |
|
|
36 |
Improving the Diagnosis of CVID by Analysis of Innate and Adaptive Signaling Pathways |
Unknown status |
NCT02680652 |
|
|
37 |
Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies |
Unknown status |
NCT01981785 |
|
|
38 |
Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes |
Unknown status |
NCT02556359 |
|
|
39 |
To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency |
Unknown status |
NCT01617122 |
|
|
40 |
Phenotype-genotype Correlation in a Sub-population of Severe Primary Immunodeficiency With Lymphoproliferation and Neutropenia |
Completed |
NCT03427593 |
|
|
41 |
Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency |
Completed |
NCT00004695 |
|
PEG-interleukin-2 |
42 |
The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency |
Completed |
NCT00015431 |
|
|
43 |
Effects of Intravenous Human Polyclonal Immunoglobulins G Infusion on Endothelial Function and Insulin Sensitivity in Humans |
Completed |
NCT03534479 |
|
Polyclonal IgG |
44 |
Serum IgG Antibody to Streptococcus Pneumoniae, Haemophilus Influenzae Type b and Tetanus Toxoid in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Infusions |
Completed |
NCT00661401 |
|
|
45 |
Construction and Validation of a Health-related Quality of Life (HR-QOL) Instrument for Patients With Primary Antibody Deficiency Disease |
Completed |
NCT02542228 |
|
|
46 |
Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis |
Completed |
NCT03259282 |
|
|
47 |
Retrospective Study of the Breadth of Donor Options for Patients With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide |
Completed |
NCT03188419 |
|
|
48 |
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease |
Completed |
NCT03211689 |
|
|
49 |
Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates |
Completed |
NCT02043379 |
|
IVIG |
50 |
Improving the Diagnosis of Common Variable Immune Deficiency by Analysis of Innate and Adaptive Signaling Pathways |
Recruiting |
NCT03335605 |
|
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Common Variable Immunodeficiency:
Embryonic/Adult Cultured Cells Related to Common Variable Immunodeficiency:
|